Extended Data Fig. 7: In vivo activity and safety profiles of IL-2^α-bias in 5 different syngeneic tumors.

(a–d) Tumor growth curves and body weight changes in B16F10 (a), LLC1 (b), CT26 (c) and EMT6 (d) tumor models after indicated treatments (n = 7 mice). (e) Wet lung weight measured from treated mice at the end of study (n = 7 mice). The center lines indicate median values, box limits indicate the 25^th and 75^th percentiles and whiskers extend 1.5x the interquartile range from 25^th and 75^th percentiles. (F-H) In vivo activities of IL-2^α-bias in MC38 tumors (n = 8 mice), related to Fig. 4e, f. Dot plots showing PD-1 and CD25 expressions on CD8⁺TILs in MC38 tumors (f), frequency and absolute number of IFN-γ⁺CD8⁺TILs (g), and enrichment fold of IFN-γ⁺% in PD-1^-CD25^-, PD-1⁺CD25^- and PD-1⁺CD25⁺ subsets of CD8⁺TILs after treatment (H). (i) Tumor growth curves showing efficacy of IL-2^α-bias in B16F10-OVA tumors (n = 6~7 mice). (J) Dot plots showing PD-1 and CD25 expressions on CD8⁺TILs in B16F10-OVA tumors. (k) OVA-tetramer⁺% in PD-1^-CD25^-, PD-1⁺CD25^- and PD-1⁺CD25⁺ subsets of CD8⁺TILs after IgG or IL-2^α-bias treatment (n = 6~7 mice). Mean + s.e.m. is presented, and p-values are calculated using two-way ANOVA for tumor growth curves (A-D and I, Tukey’s multiple comparisons test) and for H and K (Šídák’s multiple comparisons test), one-way ANOVA (Tukey’s multiple comparisons test) for box plots (E), and two-sided t-test for bar graphs (G).

Source data